Progress of liver injury caused by new oral anticoagulants
10.3760/cma.j.issn.1008-5734.2018.04.009
- VernacularTitle:新型口服抗凝药物致肝损伤研究进展
- Author:
Xiang HUI
1
;
Qingqing FAN
;
Yan DUAN
;
Dihong YANG
;
Weihong GE
Author Information
1. 210008 南京大学医学院附属鼓楼医院药学部;211198南京,中国药科大学基础医学与临床药学学院
- Publication Type:Journal Article
- Keywords:
Anticoagulants;
Dabigatran;
Factor Xa inhibitors;
Drug-induced liver injury
- From:
Adverse Drug Reactions Journal
2018;20(4):289-295
- CountryChina
- Language:Chinese
-
Abstract:
Novel oral anticoagulants (NOAC)include direct thrombin inhibitors (ximelagatran and dabigatran etexilate ) and coagulation factor Xa inhibitors (rivaroxaban, apixaban and edoxaban ). Ximelagatran was withdrawn from the market in 2006 because of its high incidence of liver injury after listing in 2004,which has aroused concern about the hepatotoxicity of NOAC. No significant evidence of hepatotoxicity was found in pre-clinical studies on dabigatran etexilate,rivaroxaban,apixaban,or edoxaban and their risks of liver injury were low. However,pre-marketing clinical studies,post-marketing literature reports,and pharmacovigilance data showed that the incidence of NOAC-related liver injury was 0.1% to 1.0%. Reports of liver adverse events related to rivaroxaban were more than those related to apixaban and dabigatran etexilate. The patients who use NOAC have underlying diseases. Once liver injury occurs,it is more serious and the mortality is higher. Clinicians should be highly vigilant. The mechanism of NOAC-related hepatotoxicity is still unclear and further study is needed in the future.
